logo image
search icon
Global Longevity and Anti-Senescence Therapy Market

Longevity and Anti-Senescence Therapy Market Size, Share & Trends Analysis Report By Therapy (Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, Others), By Application, By Region, And By Segment Forecasts, 2024-2031

Report ID : 1354 | Published : 2024-02-13 | Pages: 185 | Format: PDF/EXCEL

The Longevity and Anti-Senescence Therapy Market Size is valued at USD 27.11 Billion in 2023 and is predicted to reach USD 44.92 Billion by the year 2031 at a 6.8 % CAGR during the forecast period for 2024-2031. 

longevity

Longevity is an effective approach focuses on the extension of health span by slowing the rate of aging. This approach is considered as the most efficient way to combat various aging-related chronic illnesses and disabling conditions. Aging comprises a rising risk of developing a number of neurodegenerative disorders, cardiovascular disease, diabetes, osteoarthritis, and cancer, which are commonly referred to as age-related diseases (ARDs). In the recent years, the development of new interventions and rejuvenation strategies to increase health span by means of supplements and pharmaceuticals targeting aging-related pathologies are in spotlight of a new branch in geriatric medicine, geroscience.  Longevity and Anti-Senescence Therapy is one of such therapy can be classified into four groups: pharmacological therapies, lifestyle related, molecular (genetic and epigenetic) and cellular.

The growing number of geriatric populations across the globe in recent years is expected to bolster demand for Longevity and Anti-Senescence Therapy Market.  According to World Population Prospects 2019 (United Nations, 2019), Global population aged 65 or over was accounted for 703 Million. Globally, geriatric population is anticipated to double by 2050 to reach 1.5 billion. Increasing number of research and investment activities in the development of longevity and anti-senescence therapies is projected to positively influence the industry’s growth over the forecast period.  Another key aspect including rising adoption of advanced technologies such as gene therapy, stem cell, and senolytics Drug Therapy is anticipated to trigger growth in near future. Escalating prevalence of target diseases, especially Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, Cancer, among the aging population is expected to assist in the growth of the market for Longevity and Anti-Senescence Therapy over the coming years.

Market Segmentation

The global Longevity and Anti-Senescence Therapy market is categorized on the basis of Therapy, Application and region.  On the basis of Therapy, the market is segmented into Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, and Others. Based on Application the market is segmented into Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, and Cancer. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.                                 

Competitive Landscape

Some Major Key Players In The Longevity and Anti-Senescence Therapy Market:

  • Acorda Therapeutics,
  • Agex Therapeutics,
  • Antoxerene,
  • Calico Life Sciences,
  • Celgene,
  • Cleara Biotech,
  • Human Longevity Inc.,
  • Insilico Medicine,
  • Oisin Biotechnology,
  • Powervision Inc.,
  • Prana Biotechnology Ltd.,
  • Proteostasis Therapeutics Inc.,
  • Recursion Pharmaceuticals,
  • Restorbio,
  • Sierra Sciences Llc,
  • Senex Biotechnology,
  • Senolytic Therapeutics,
  • Spotlight Bioscience,
  • A. Sciences,
  • Unity Biotechnology,
  • Alkahest, Inc.,
  • Stealth BioTherapeutics,
  • BIOPHYTIS BSA,
  • SIWA Therapeutics,
  • Rejuveron Life Sciences AG,
  • Rubedo Life Sciences, Inc,
  • Lineage Cell Therapeutics,
  • Juvenescence Life,
  • Longevity Biotech CohBar, Inc. (CWBR),
  • Genome Protection Inc.,
  • Navitor Pharmaceuticals, Inc.,
  • Elevian, Inc.,

 

Longevity and Anti-Senescence Therapy Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 27.11 Billion

Revenue Forecast In 2031

USD 44.92 Billion

Growth Rate CAGR

CAGR of 6.8 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Therapy, Applications

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Acorda Therapeutics, Agex Therapeutics, Antoxerene, Calico Life Sciences, Celgene, Cleara Biotech, Human Longevity Inc., Insilico Medicine, Oisin Biotechnology, Powervision Inc., Prana Biotechnology Ltd., Proteostasis Therapeutics Inc., Recursion Pharmaceuticals, Restorbio, Sierra Sciences Llc, Senex Biotechnology, Senolytic Therapeutics, Spotlight Bioscience, T.A. Sciences, Unity Biotechnology, Alkahest, Inc., Stealth BioTherapeutics, BIOPHYTIS BSA, SIWA Therapeutics, Rejuveron Life Sciences AG, Rubedo Life Sciences, Inc, Lineage Cell Therapeutics, Juvenescence Life, Longevity Biotech CohBar, Inc. (CWBR), Genome Protection Inc., Navitor Pharmaceuticals, Inc., Elevian, Inc., Other Prominent Players.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope


1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Longevity and Anti-Senescence Therapy Market Snapshot

Chapter 4. Global Longevity and Anti-Senescence Therapy Market Variables, Trends & Scope


4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Key Healthcare Companies
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Therapy Estimates & Trend Analysis


5.1. By Therapy & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapy:
5.2.1. Senolytic Drug Therapy
5.2.2. Gene Therapy
5.2.3. Cell Therapy
5.2.4. Mitochondrial Therapy
5.2.5. Immunotherapy
5.2.6. Others

Chapter 6. Market Segmentation 1: By Applications Estimates & Trend Analysis


6.1. By Applications & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Applications:
6.2.1. Longevity
6.2.2. Senescence Inhibition
6.2.3. Cardiovascular Diseases
6.2.4. Neural Degenerative Diseases
6.2.5. Ophthalmology Disorders
6.2.6. Cancer

Chapter 7. Longevity and Anti-Senescence Therapy Market Segmentation 3: Regional Estimates & Trend Analysis


7.1. North America
7.1.1. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Therapy, 2024-2031
7.1.2. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Applications, 2024-2031
7.1.3. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.2.2. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.2.3. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.3.2. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.3.3. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million), 2024-2031
7.4.2. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.4.3. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million) 2024-2031
7.5.2. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.5.3. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031


Chapter 8. Competitive Landscape


8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles

8.2.1. Acorda Therapeutics
8.2.2. Agex Therapeutics
8.2.3. Antoxerene
8.2.4. Calico Life Sciences
8.2.5. Celgene
8.2.6. Cleara Biotech
8.2.7. Human Longevity Inc.
8.2.8. Insilico Medicine
8.2.9. Oisin Biotechnology
8.2.10. Powervision Inc.
8.2.11. Prana Biotechnology Ltd.
8.2.12. Proteostasis Therapeutics Inc.
8.2.13. Recursion Pharmaceuticals
8.2.14. Restorbio
8.2.15. Sierra Sciences Llc
8.2.16. Senex Biotechnology
8.2.17. Senolytic Therapeutics
8.2.18. Spotlight Bioscience
8.2.19. T.A. Sciences
8.2.20. Unity Biotechnology
8.2.21. Alkahest, Inc.
8.2.22. Stealth BioTherapeutics
8.2.23. BIOPHYTIS BSA
8.2.24. SIWA Therapeutics
8.2.25. Rejuveron Life Sciences AG
8.2.26. Rubedo Life Sciences, Inc
8.2.27. Lineage Cell Therapeutics
8.2.28. Juvenescence Life
8.2.29. Longevity Biotech CohBar, Inc. (CWBR)
8.2.30. Genome Protection Inc.
8.2.31. Navitor Pharmaceuticals, Inc.
8.2.32. Elevian, Inc.
8.2.33. Velabs Therapeutics
8.2.34. Other Prominent Player

Market Segmentation

Global Longevity and Anti-Senescence Therapy Market Based on Therapy

  • Senolytic Drug Therapy
  • Gene Therapy
  • Cell Therapy
  • Mitochondrial Therapy
  • Immunotherapy
  • Others 

LONGEVITY

Global Longevity and Anti-Senescence Therapy Market Based on Application

  • Longevity
  • Senescence Inhibition
  • Cardiovascular Diseases
  • Neural Degenerative Diseases
  • Ophthalmology Disorders
  • Cancer

 

Global Longevity and Anti-Senescence Therapy Market Based on Region

Europe

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America

  • U.S.
  • Canada

Asia Pacific

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Longevity and Anti-Senescence Therapy Market Size?

The Longevity and Anti-Senescence Therapy Market is expected to grow at a 6.8 % CAGR during the forecast period for 2024-2031.

Acorda Therapeutics, Agex Therapeutics, Antoxerene, Calico Life Sciences, Celgene, Cleara Biotech, Human Longevity Inc., Insilico Medicine, Others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4486
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach